In its first year, MicroTex has focus on building the foundations required to support this ambition.
A key step has been the definition of three translational platforms: the cornea, proximal airway, and distal lung. These provide a clear, clinically relevant framework for interdisciplinary research, bringing together engineering, chemistry, photonics, biology, and clinical science to address challenging environments where localised drug delivery and measurement are essential.
MicroTex has also implemented a structured approach to Target Product Profiles (TPPs). TPPs define the intended use, performance, and clinical context of emerging technologies. Within the programme, they align research with clinical and industry needs, guide development towards demonstrators, and support evidence-based decision-making.
To support delivery, governance structures have been established, including an Independent Advisory Board providing external oversight and strategic guidance. In parallel, five Action Groups—Translation and Impact; Training and Development; Outreach and Advocacy; Partnerships and Collaboration; and Funding and Awards—enable coordinated activity and distributed leadership across the Hub.
MicroTex is embedded within the Baillie Gifford Pandemic Science Hub, providing access to shared infrastructure, regulatory expertise, and translational pathways in infection and inflammation. This positioning strengthens the programme’s ability to move from early-stage research towards clinical application.
International collaboration is also a priority, including engagement with Aravind Eye Care System to support evaluation in diverse clinical settings and accelerate global translation.
Together, these developments position MicroTex for its next phase: advancing platform-specific technologies, generating early human-relevant data, and strengthening pathways to impact.